| Description | Ciprofloxacinisafluoroquinoloneantibiotic,exhibitingpotentantibacterialactivity. |
|---|---|
| InVitro | Ciprofloxacinisafluoroquinoloneantibiotic,exhibitingpotentantibacterialactivity[1].Ciprofloxacin(CIP)showspotentactivityagainstY.pestiswithMIC90of0.03μg/mL[2]. |
| InVivo | Ciprofloxacin(1mg/L)inducesglutathione-S-transferase(GST)activity,incontrastwithinhibitedGSTandCatalase(CAT)oflarvaeexposedtoenrofloxacin.Ciprofloxacin(≥10μg/L)andenrofloxacinareecotoxicfordevelopment,growth,detoxifying,andoxidativestressenzymesinanuranamphibianlarvae[1].Inamurinemodelofpneumonicplague,Ciprofloxacin(30mg/kg,i.p.)resultsinadrugexposurewhichissimilartothedrugexposureobservedinhumanfollowinga500mgdoseoforalCiprofloxacin.IntraperitonealCiprofloxacinreducesthelungbacterialloadcomparetocontrolstreatedwithintraperitonealPBS[3]. |
| ClinicalTrial | ViewMoreCollapse |
| References |
|
| PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellAssay [2] | Antibiotics(includingCiprofloxacin)areseriallydiluted2-foldin50μLofcation-adjustedMueller-Hintonbroth(CAMHB).Theantibiotic(includingCiprofloxacin)rangesare8to0.004μg/mLor64to0.03μg/mLbasedonafinalwellvolumeof100μLafterinoculation. BacterialinoculaarepreparedbysUSPendingcoloniesintoMueller-Hintonbroth(CAMHB)(containingCiprofloxacin)from18to24h(B.anthracis)or42to48h(Y.pestis)onsheepbloodagar(SBA)platesthatareincubatedat35°C.SuspendedculturesaredilutedwithCAMHBtoabacterialcelldensityof105CFU/mLadjustedbasedontheopticaldensityat600nm.Toeachwellofthe96-wellplate,50μLofdilutionsisaddedforafinalinoculumof~5×104CFU/well.Platesareincubatedat35°C.MICsaredeterminedvisuallyat18to24h(B.anthracis)or42to48h(Y.pestis)andalsobyabsorbanceat600nm[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||||||||||||
| AnimalAdmiNISTration [3] | FemaleBALB/cAnNCrl(BALB/c)mice,8to10weeksoldand20g(±4g)areusedinthisassay.AsingledoseofCiprofloxacin(30mg/kg)isadministeredtomice(n=30)viatheintraperitoneal(i.p.)route.Themice(n=3/timepoint/group)areculledat1,10,20,or30minand1,1.5,2,4,8,12hfollowingCiprofloxacinadministrationand1,15,or30minand1,2,4,6,10,18,or24hfollowingDRCFIorCFIadministration.Bloodsamplingpointsarechosenbasedupontheshorthalf-lifeofCiprofloxacinandlongerhalf-lifeofCFI.Bloodandlungs(wholeorgan)arecollectedpostmortemforanalysis.ThelungdosesfollowingCFIorDRCFIadministrationarecalculatedusingtheconcentrationofCiprofloxacininthelungsamplesat1minpost-administration[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References |
|
